RHHBY News and Press, Roche Holding Ltd ADR From 03/06/26

2026-03-06 10:45:02 ET More on Pfizer, Merck, etc. Pfizer: Obesity Hype And Vaccine Policy Shocks AbbVie: Stabilizes Near $233 While Testing Resistance Pfizer's Portfolio Renewal In Progress - High Yields For The Patient China approves Pfizer’s GLP-1 d...

Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms G azyva has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE)...

2026-03-05 14:13:20 ET More on Roche Holding, Zealand Pharma Zealand Pharma A/S 2025 Q4 - Results - Earnings Call Presentation Zealand Pharma A/S (ZLDPF) Q4 2025 Earnings Call Transcript Roche Holding AG (RHHBY) Shareholder/Analyst Presentation Roche CEO Schi...

– Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerability – – At the maximally effective dose, there were no cases of vomiting and no treatment discontinuations d...

New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools PR Newswire Global survey of 4,326 people with diabetes shows how the unpredictability and mental burden associated with managing the condition negat...

2026-03-03 13:50:10 ET The last time I spoke about Prothena Corporation plc ( PRTA ), it was in a Seeking Alpha article entitled " Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place ." I went over two of its main clinical programs, which were ...

2026-03-03 11:35:08 ET More on Roche Roche Holding AG (RHHBY) Shareholder/Analyst Presentation Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript ClearBridge International Growth ACWI Ex-US S...

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with FENhance 2 results showing 59% reduction - - FENhance 1 is the final study readout of the ...

2026-02-27 08:00:00 ET Shares of Regeneron Pharmaceuticals ( REGN ), my favorite on the monoclonal antibodies market, have risen 11.5% since the article "Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?" .... Read the full article on Seeking Alpha ...

2026-02-26 13:35:52 ET More on leading drugmakers Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade) Merck: Why Investors Should Remain Bullish Despite Patent Risks ...